PRL-3 Inhibitor 2

• CAT Number: I031739
• CAS Number: 577962-95-9
• Molecular Formula: C15H11N3O4
• Molecular Weight: 297.27
• Purity: ≥95%
• Synonyms: 4-[2-[(Z)-(2,5-dioxoimidazolidin-4-ylidene)methyl]pyrrol-1-yl]benzoic acid
• IUPAC Name: 4-[2-[(E)-(2,5-dioxoimidazolidin-4-ylidene)methyl]pyrrol-1-yl]benzoic acid
• InChI: InChI=1S/C15H11N3O4/c19-13-12(16-15(22)17-13)8-11-2-1-7-18(11)10-5-3-9(4-6-10)14(20)21/h1-8H,(H,20,21)(H2,16,17,19,22)/b12-8+
• InChIKey: WMOKBKUDIRNAKD-XYOKQWHBSA-N
• SMILES: C1=CN(C(=C1)/C=C/2\C(=O)NC(=O)N2)C3=CC=C(C=C3)C(=O)O

PRL-3 Inhibitor 2（Cat No.:I031739）is a selective small molecule inhibitor targeting the protein tyrosine phosphatase PRL-3 (protein tyrosine phosphatase type 4A), which is associated with cancer metastasis and poor prognosis. By inhibiting PRL-3, this compound aims to interfere with the signaling pathways that promote tumor cell migration, invasion, and angiogenesis. It is primarily being studied for its potential therapeutic applications in cancer, particularly in treating metastatic cancers where PRL-3 plays a significant role. Ongoing research focuses on evaluating its efficacy, safety, and potential as a targeted cancer therapy.